Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 1
1974 2
1975 2
1980 1
1981 2
1985 1
1988 1
1989 2
1991 1
1992 1
1994 1
1997 2
1998 1
2001 1
2003 2
2004 3
2005 4
2006 9
2007 17
2008 15
2009 20
2010 25
2011 28
2012 33
2013 21
2014 29
2015 34
2016 28
2017 25
2018 33
2019 30
2020 41
2021 33
2022 40
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20658586

457 results

Results by year

Filters applied: . Clear all
Page 1
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Risitano AM, et al. Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019. Front Immunol. 2019. PMID: 31258525 Free PMC article. Review.
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Kanakura Y, et al. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12. Int J Hematol. 2011. PMID: 21222185 Clinical Trial.
Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M, Martin Merinero H, López A, Anter J, García SP, Ataúlfo Gonzalez-Fernández F, Forés R, Lopez-Trascasa M, Villegas A, Ojeda E, Rodríguez de Córdoba S. Subías Hidalgo M, et al. Immunobiology. 2017 Feb;222(2):363-371. doi: 10.1016/j.imbio.2016.09.002. Epub 2016 Sep 13. Immunobiology. 2017. PMID: 27644115 Free article.
457 results